Aviva
ENTA icon

Aviva’s Enanta Pharmaceuticals ENTA Stock Holding History

Aviva’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,885
Closed -$1.23M – 899
2021
Q1 		$1.23M Sell
24,885
-3,392
-12% -$169K 0.01% 806
2020
Q4 		$1.19M Sell
28,277
-22,924
-45% -$1.01M 0.01% 836
2020
Q3 		$2.34M Buy
51,201
+4,631
+10% +$224K 0.01% 658
2020
Q2 		$2.34M Sell
46,570
-28,464
-38% -$1.47M 0.01% 625
2020
Q1 		$3.86M Buy
75,034
+44,451
+145% +$2.37M 0.03% 479
2019
Q4 		$1.89M Buy
+30,583
New +$1.9M 0.01% 781

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Aviva's ENTA Position: Q2 2021 in Review

Aviva sold out of Enanta Pharmaceuticals (ENTA) in Q2 2021, closing a stake of 24,885 shares — an estimated $1.23M sold.

Aviva first reported a position in ENTA in Q4 2019 and held it in 6 quarters. The position peaked at $3.86M in Q1 2020. 151 funds tracked by Wall St. Rank hold ENTA as of Q2 2021.

  • Aviva reported no remaining Enanta Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 24,885 Enanta Pharmaceuticals shares in Q2 2021, an estimated $1.23M.
  • Aviva first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Aviva's Enanta Pharmaceuticals position peaked at $3.86M in Q1 2020.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.